To the Editor: Autoantibodies against pancreatic islet antigens are major biomarkers of type 1 diabetes and have found widespread application in both diagnostics and research settings. Known type 1 diabetes autoantigens targeted by antibody responses include proteins linked to either the insulin or neurotransmitter secretory pathways of pancreatic beta cells. Recently, the presence of autoantibodies against the cytokine IL-2 was reported in individuals with type 1 diabetes [1] . Autoantibodies against other cytokines, such as IFN-γ, granulocyte colony-stimulating factor, IL-6, IL-17 and IL-22, have been described in a variety of other diseases, including autoimmune syndromes sometimes presenting together with type 1 diabetes [2] . In an original report by Pérol et al [1] , IL-2 autoantibodies, measured by a direct ELISA assay, were suggested to be present in the NOD mouse, where they correlated with disease development, and in around 25% of humans at onset of type 1 diabetes. To investigate the presence of IL-2 autoantibodies in human type 1 diabetes, we developed a novel assay based on the luciferase immunoprecipitation system (LIPS) format. The LIPS is a derivative of the radiobinding assay (RBA), the gold standard method for the measurement of type 1 diabetes-associated autoantibodies, in which serum antibodies are used to immunoprecipitate radiolabelled antigens in liquid phase. In the LIPS, the use of radiolabelled tracers is superseded in favour of chimeric recombinant antigens tagged with a luciferase reporter [3] . We generated a recombinant IL-2 (NLuc-IL-2) fused to a NanoLuc luciferase reporter (Promega, Madison, WI, USA) and expressed NLuc-IL-2 in mammalian eukaryotic cells as a protein secreted in the culture medium at a concentration of 204 ng/ml, as quantified using a commercially available sandwich IL-2 ELISA kit. The biological activity of NLuc-IL-2 was verified by flow cytometry using a carboxyfluorescein succinimidyl ester (CFSE)-based cell proliferation assay. We incubated 6 × 10 5 cells from a buffy coat preparation for 1 week and observed a proliferation in 52% of lymphocytes treated with 0.7 ng of NLuc-IL-2 vs 11% in untreated cells and >62% in cells treated with commercial recombinant human IL-2. Using the LIPS, we then measured IL-2 autoantibodies in serum from individuals with new-onset type 1 diabetes (n = 60, median age 13.9 years [interquartile range 7.9-14.9 years]), diagnosed according to the ADA criteria, and from control individuals without diabetes (n = 61, median age 22.1 years [interquartile range 16.7-26.1 years]) collected at the San Raffaele Scientific Institute between 2012 and 2016 within the study protocol TIGET004-DRI003. The study was approved by the local ethics committee, all participants gave informed consent and the investigations were carried out in accordance with the Declaration of Helsinki as revised in 2000. Serial twofold dilutions of the anti-human IL-2 monoclonal antibody MQ1-17H12 [1] , ranging from 1:1000 to 1:6,348,000, were used to build a standard curve and convert raw results in arbitrary units (Fig. 1a) . Our results show that binding to NLuc-IL-2 could not be detected in any of the tested type 1 diabetes samples above the adopted threshold for positivity, corresponding to the 99th percentile of values observed in control samples as commonly adopted in RBA for other type 1 diabetes-associated autoantibodies (Fig. 1b) . The analysis of the area under the receiver operator characteristic curve (ROC-AUC) confirmed that the measurement of IL-2 antibodies in a liquid phase assay could not discriminate between individuals with and without type 1 diabetes (anti-IL-2 LIPS ROC-AUC 0.537 [95% CI 0.4341, 0.6405], p = 0.479). The size of the cohorts analysed provided a >80% power to detect a difference in the proportion of IL-2 autoantibodypositive individuals in the two groups as large as the one reported in previous studies. The use of commercial recombinant IL-2 to compete for binding to NLuc-IL-2 in LIPS of sera with the highest signal again did not discriminate between samples from individuals with and without diabetes. Therefore, we cannot confirm the original findings of the presence of anti-IL-2 autoantibodies in type 1 diabetes claimed by Pérol et al [1] and based on a solid-phase immunoassay. Several possible mechanistic explanations have been previously advanced to explain the lack of concordance between liquid-phase and solid-phase assay results [4] . However, it is important to note that, more than once, liquid-phase assays have in the past outperformed classical solid-phase assays for measurement of type 1 diabetes autoantibody responses [5] . In conclusion, our results do not support the presence of IL-2 autoantibodies or their relevance for the pathogenesis of human type 1 diabetes. 
